New Delhi, June 1 -- In a historic first for perioperative oncology, Johnson & Johnson's apalutamide slashed metastasis risk by 20% and achieved near-complete cancer clearance nine times more often than standard hormone therapy alone.

Johnson & Johnson has made one of the most closely watched oncology announcements from ASCO 2026, reporting that its prostate cancer therapy ERLEADA, also known as apalutamide, significantly reduced the risk of metastasis or death when used before and after surgery. The results come from the Phase 3 PROTEUS study, a large randomized trial involving patients with high-risk localized or locally advanced prostate cancer who were eligible for radical prostatectomy. For decades, surgery has remained a core treat...